

4DMEDICAL COMMENCES CLINICAL TRIAL STUDYING XV LVAS AT JOHNS HOPKINS SCHOOL OF MEDICINE

Highlights

- 4DMedical has secured a clinical trial, and subsequently commenced patient recruitment and scanning, at the globally renowned Johns Hopkins School of Medicine in the U.S.
- The clinical trial will focus on validating the clinical benefit of XV Lung Ventilation Analysis Software (XV LVAS™) in patients with chronic obstructive pulmonary disease (COPD)
- COPD is the third highest cause of death in the world and represents one of the largest indications for 4DMedical's non-invasive, low dose technology
- 4DMedical currently has 8 clinical trials with Institutional Board Review (IRB) approval in the U.S. studying XV LVAS and contrast-free Ventilation Perfusion (VQ)
- Clinical trials and pilots will play an important role in commercialisation by increasing awareness and adoption of XV LVAS at leading medical institutions globally

29 June 2021: 4DMedical Limited (ASX:4DX, "4DMedical" or the "Company"), a medical technology company focused on commercialising its patented respiratory imaging platform, is pleased to announce it has commenced patient recruitment and scanning in its clinical trial at globally leading medical research institute, Johns Hopkins School of Medicine, located in Baltimore, Maryland, U.S.

The clinical trial is expected to be completed over the course of 2021 and is focused on providing further evidence of the capability of XV LVAS™ to evaluate and monitor patients suffering from COPD.

Referring to a group of progressive lung diseases such as emphysema and chronic bronchitis, COPD is the third largest cause of death in the world affecting 3.2% of the global population and accounting for 5.7% of global deaths¹. COPD is characterised by the varying severity of chronic airflow obstruction, typically caused by long-term exposure to air pollution or cigarette smoke, and is rarely reversible.

By integrating with Johns Hopkins existing imaging equipment, XV LVAS is being utilised to detect early changes in airway function, disease progression and regional ventilation defects in the lungs of approximately 15 COPD patients. The results will be compared to traditional respiratory diagnostics such as spirometry and computed tomography (CT).

With the addition of Johns Hopkins School of Medicine, 4DMedical currently has a total of eight clinical trials with at least IRB approval status in the U.S. This includes seven studying XV LVAS and one studying the Company's contrast-free VQ product. Other clinical trials currently scanning patients include Cleveland Clinic, Duke University and University of Miami, as well as Vanderbilt University Medical Center where XV LVAS is being used to study the effects of environmental exposure on the lungs of U.S. war veterans.

4DMedical Founder and CEO Andreas Fouras said:

"The recommencement of U.S. hospital workflows has substantially accelerated our clinical trial program at some of the world's most reputable medical research institutes, including Johns Hopkins School of Medicine.

-

¹ https://www.who.int/news-room/fact-sheets/detail/chronic-obstructive-pulmonary-disease-(copd)

Clinical trials, along with clinical pilots, will form the important foundation for 4DMedical to capture a sizeable portion of the global respiratory diagnostic market by validating our technology in some of the world's most prevalent and costly lung diseases.

"As one of the leading contributors of death around the world, COPD represents the largest indications for 4DMedical's non-invasive technology. Importantly, XV LVAS offers a powerful new diagnostic imaging tool for COPD given the requirement of clinicians to frequently monitor airflow changes in patients."

ENDS

Authorised by Andreas Fouras, Managing Director and CEO.

Contacts:

Corporate Investor Media

Charlene Stahr Simon Hinsley Matthew Wright
Company Secretary + 61 401 809 653 + 61 451 896 420

companysecretary@4dmedical.com simon@nwrcommunications.com.au matt@nwrcommunications.com.au

About 4DMedical:

Based in Melbourne, Australia and Los Angeles, USA, 4DMedical (formerly 4Dx) was founded in 2012 and is listed on the Australian Securities Exchange (ASX: 4DX).

4DMedical is a medical technology company aiming to deliver the global gold standard in respiratory diagnostics for all lung disorders including: coronavirus, asthma, chronic obstructive pulmonary disease (COPD), cystic fibrosis and cancer.

The unique 4DMedical technology accurately and quickly scans lung function as the patient breathes, to assist in providing sensitive, early diagnosis, and to monitor changes over time. Our Software-as-a-Service (SaaS) scans deliver much more complete results, showing even subtle variations in lung function down to the finest details, using lower levels of radiation than traditional methods.

Respiratory diagnosis is a US\$31 billion per annum global industry. Through its technology 4DMedical provides clinicians with greater insights into diseases of the lung. 4DMedical is focused on providing better information to doctors and patients about lung function. Better information means better decisions, and better outcomes.